Biochemistry
Research and development
The Biochemistry Department of the International Center for Neurosciences and Genomic Medicine develops, in addition to its healthcare work, an important scientific activity. Since its creation in 1992, it has carried out its own R&D&I projects and has participated in several externally funded national and international research projects, as well as taking part in clinical trials of important pharmaceutical companies.
Currently, his scientific work is mainly focused on the following fields:
Study of biomarkers in Alzheimer's disease and other dementias.
Study of biochemical biomarkers in the early diagnosis, monitoring and prognosis of diseases related to aging, such as Alzheimer's disease and other dementias.
Recent studies have focused on the evaluation of β-amyloid protein, oxidative stress and vascular risk in dementias and their association with the genetics involved in these pathologies.
Development of biopanels for risk and early detection of prevalent diseases.
Design of exclusive biochemical profiles for clinical use for risk detection, early diagnosis and follow-up of prevalent diseases such as metabolic syndrome, osteoporosis, oxidative stress, cardiovascular risk, and diseases related to alterations in neurotransmitters, among others.
The use of biomarkers related to different etiopathogenic lines of the same pathology offers us a broader vision of the status of the disease. The inclusion of risk factors that favor the development, and that in most cases are modifiable, allow us to minimize or delay the evolution of these diseases.
Bioproduct development
In collaboration with other R&D&I departments of the Euroespes Group, the Biochemistry and Clinical Analysis laboratory is working on the development of nutraceuticals with beneficial health properties.
From the biochemical point of view, different sensitive and specific biomarkers are selected and analyzed in the evaluation of the biological properties of each of the nutraceuticals under development.